Literature DB >> 35245435

MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.

Sarah Naomi Olsen1, Laura Godfrey1, James P Healy1, Yoolim A Choi1, Yan Kai1, Charles Hatton1, Florian Perner2, Elena L Haarer1, Behnam Nabet3, Guo-Cheng Yuan4, Scott A Armstrong5.   

Abstract

MLL rearrangements produce fusion oncoproteins that drive leukemia development, but the direct effects of MLL-fusion inactivation remain poorly defined. We designed models with degradable MLL::AF9 where treatment with small molecules induces rapid degradation. We leveraged the kinetics of this system to identify a core subset of MLL::AF9 target genes where MLL::AF9 degradation induces changes in transcriptional elongation within 15 minutes. MLL::AF9 degradation subsequently causes loss of a transcriptionally active chromatin landscape. We used this insight to assess the effectiveness of small molecules that target members of the MLL::AF9 multiprotein complex, specifically DOT1L and MENIN. Combined DOT1L/MENIN inhibition resembles MLL::AF9 degradation, whereas single-agent treatment has more modest effects on MLL::AF9 occupancy and gene expression. Our data show that MLL::AF9 degradation leads to decreases in transcriptional elongation prior to changes in chromatin landscape at select loci and that combined inhibition of chromatin complexes releases the MLL::AF9 oncoprotein from chromatin globally.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DOT1L inhibition; MENIN inhibition; MLL-fusions; epigenetics; gene regulation; leukemia; targeted protein degradation

Mesh:

Substances:

Year:  2022        PMID: 35245435      PMCID: PMC9044330          DOI: 10.1016/j.molcel.2022.02.013

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   19.328


  52 in total

1.  The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin.

Authors:  Deniz T Zeisig; Claudia B Bittner; Bernd B Zeisig; Maria-Paz García-Cuéllar; Jay L Hess; Robert K Slany
Journal:  Oncogene       Date:  2005-08-18       Impact factor: 9.867

2.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

Authors:  Matthew G Guenther; Lee N Lawton; Tatiana Rozovskaia; Garrett M Frampton; Stuart S Levine; Thomas L Volkert; Carlo M Croce; Tatsuya Nakamura; Eli Canaani; Richard A Young
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

Review 3.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

4.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes.

Authors:  Akihiko Yokoyama; Michael L Cleary
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

5.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

6.  hDOT1L links histone methylation to leukemogenesis.

Authors:  Yuki Okada; Qin Feng; Yihui Lin; Qi Jiang; Yaqiang Li; Vernon M Coffield; Lishan Su; Guoliang Xu; Yi Zhang
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

7.  Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Authors:  Tomasz Cierpicki; Laurie E Risner; Jolanta Grembecka; Stephen M Lukasik; Relja Popovic; Monika Omonkowska; David D Shultis; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Nat Struct Mol Biol       Date:  2009-12-13       Impact factor: 15.369

8.  HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Authors:  Joerg Faber; Andrei V Krivtsov; Matthew C Stubbs; Renee Wright; Tina N Davis; Marry van den Heuvel-Eibrink; Christian M Zwaan; Andrew L Kung; Scott A Armstrong
Journal:  Blood       Date:  2008-12-03       Impact factor: 22.113

9.  Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.

Authors:  Christina M Hughes; Orit Rozenblatt-Rosen; Thomas A Milne; Terry D Copeland; Stuart S Levine; Jeffrey C Lee; D Neil Hayes; Kalai Selvi Shanmugam; Arindam Bhattacharjee; Christine A Biondi; Graham F Kay; Nicholas K Hayward; Jay L Hess; Matthew Meyerson
Journal:  Mol Cell       Date:  2004-02-27       Impact factor: 17.970

10.  Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase.

Authors:  Mark D Allen; Charles G Grummitt; Christine Hilcenko; Sandra Young Min; Louise M Tonkin; Christopher M Johnson; Stefan M Freund; Mark Bycroft; Alan J Warren
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

View more
  4 in total

1.  Temporal resolution of gene derepression and proteome changes upon PROTAC-mediated degradation of BCL11A protein in erythroid cells.

Authors:  Stuti Mehta; Altantsetseg Buyanbat; Yan Kai; Ozge Karayel; Seth Raphael Goldman; Davide Seruggia; Kevin Zhang; Yuko Fujiwara; Katherine A Donovan; Qian Zhu; Huan Yang; Behnam Nabet; Nathanael S Gray; Matthias Mann; Eric S Fischer; Karen Adelman; Stuart H Orkin
Journal:  Cell Chem Biol       Date:  2022-07-14       Impact factor: 9.039

2.  Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.

Authors:  Sandra Cantilena; Luca Gasparoli; Deepali Pal; Olaf Heidenreich; Jan-Henning Klusmann; Joost H A Martens; Alexandre Faille; Alan J Warren; Mawar Karsa; Ruby Pandher; Klaartje Somers; Owen Williams; Jasper de Boer
Journal:  Clin Transl Med       Date:  2022-06

3.  IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.

Authors:  Brandon J Aubrey; Jevon A Cutler; Wallace Bourgeois; Katherine A Donovan; Shengqing Gu; Charlie Hatton; Sarah Perlee; Florian Perner; Homa Rahnamoun; Alexandra C P Theall; Jill A Henrich; Qian Zhu; Radosław P Nowak; Young Joon Kim; Salma Parvin; Anjali Cremer; Sarah Naomi Olsen; Nicholas A Eleuteri; Yana Pikman; Gerard M McGeehan; Kimberly Stegmaier; Anthony Letai; Eric S Fischer; X Shirley Liu; Scott A Armstrong
Journal:  Nat Cancer       Date:  2022-05-09

Review 4.  The Role of DOT1L in Normal and Malignant Hematopoiesis.

Authors:  Olivia Arnold; Karina Barbosa; Aniruddha J Deshpande; Nan Zhu
Journal:  Front Cell Dev Biol       Date:  2022-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.